AstraZeneca Diabetes Drug Combination Shows Promise in Study

Updated on
  • Bydureon and Forxiga reduced weight, blood pressure in trial
  • Combination may be additional option before insulin treatment

AstraZeneca Plc said a combination of two diabetes medications significantly lowered blood sugar, weight and blood pressure in a study that will support its use to delay insulin treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.